Entry into cycle, as shown by an increase in cyclin D1 levels, also occurred when quiescent ovarian cancer cells were treated for 24-98 hours with either of two Mirk kinase inhibitors, EHT5372 or EHT6840 (Fig.1C, lower). Here, CCND1 is linked to ovarian cancer.